What Tier Drug Is Metformin and What Does It Mean?

Generic metformin is almost universally placed on Tier 1 of insurance formularies in the United States, meaning it carries the lowest possible copay for the patient. On most plans that translates to somewhere between $0 and $10 for a 30-day supply, and sometimes even less through retail discount programs. That Tier 1 status reflects metformin’s position as an inexpensive, off-patent generic that major clinical guidelines recommend as the first medication to try for type 2 diabetes. But “Tier 1” is not a single fixed category across the entire healthcare system, and the practical meaning of that label shifts depending on your plan, your formulation, and what you’re taking metformin for.

How Drug Tiers Work

Insurance plans organize the drugs they cover into a ranked list called a formulary. Each rank, or tier, corresponds to a different cost-sharing level for the patient. While there is no universal standard, most commercial and Medicare Part D plans use a structure of three to six tiers. Tier 1 is reserved for preferred generics, the cheapest medications on the list. Tier 2 holds non-preferred generics or preferred brand-name drugs. Tier 3 and above are where you find non-preferred brands and specialty medications, with sharply rising copays or coinsurance at each step.

The decisions about which drugs land on which tier are largely made by pharmacy benefit management companies, or PBMs, working on behalf of insurers. PBMs aggregate the bargaining power of the millions of lives covered under their contracts to negotiate prices with drug manufacturers and pharmacies, and they design the coverage terms that determine where a medication sits on the formulary.¹ A drug’s tier placement is driven by a mix of clinical evidence, the availability of cheaper alternatives in the same class, and the rebates the PBM negotiates with manufacturers. For a drug like generic metformin, which has been off patent for decades and costs pennies per tablet to produce, there is almost no scenario in which a PBM would place it anywhere other than the lowest tier.

Why Metformin Lands at the Bottom of the Formulary

Metformin earned its Tier 1 spot through a combination of clinical reputation and rock-bottom manufacturing cost. It is recommended as the first-line oral treatment for type 2 diabetes by both the American Diabetes Association and the European Association for the Study of Diabetes.² When a medication is the consensus starting point for one of the most common chronic diseases in the world, and dozens of manufacturers compete to sell it as a generic, the price collapses. That makes it an easy choice for the preferred tier.

For patients, this means that filling a standard metformin prescription for immediate-release tablets is one of the cheapest transactions in American healthcare. Many plans set the Tier 1 copay at $0 to $10 for a month’s worth. Some employer-sponsored plans waive the copay entirely for first-line diabetes medications because keeping patients on them saves money downstream. Even outside of insurance, major retail pharmacies have long included metformin in generic discount programs that offer certain chronic-disease medications for around $4 per month or $10 for a 90-day supply.³

When Metformin Is Not Tier 1

The generic immediate-release tablet is the version that virtually every plan places on Tier 1. But metformin comes in several formulations, and not all of them get the same treatment. Extended-release (ER) tablets, which many patients prefer because they tend to cause less stomach upset, are also available as generics and are usually still Tier 1 or Tier 2. However, brand-name formulations tell a different story.

Liquid metformin, sold under the brand name Riomet ER, is a notable example. Because it remains a branded product without a widely available generic equivalent, it is rarely placed on Tier 1. Patients who need a liquid form due to difficulty swallowing tablets should expect Tier 3 placement or a prior authorization requirement.⁴ Brand-name Glucophage, the original metformin product, is technically still available but rarely prescribed since the generics are identical in active ingredient and far cheaper. If a doctor writes a brand-name-only prescription, the plan will typically cover it at a higher tier or require a step-therapy protocol showing that the generic was tried first.

The practical takeaway is straightforward: if your prescription says “metformin HCl” in standard tablet form, you are almost certainly getting Tier 1 pricing. If it specifies a brand name or a non-standard formulation, check with your plan before filling it, because the cost difference can be substantial.

Off-Label Uses and Coverage Complications

Metformin’s Tier 1 placement is built around its approved indication for type 2 diabetes. But doctors prescribe it for a range of other conditions, and those off-label uses can create friction with insurance coverage even though the drug itself is cheap.

Polycystic ovary syndrome, or PCOS, is probably the most common off-label use. The American College of Obstetricians and Gynecologists supports metformin for managing menstrual irregularity and aiding ovulation in PCOS patients. When a prescription is submitted with a PCOS diagnosis code rather than a diabetes code, some plans flag it for prior authorization. In most cases, including the correct diagnostic code on the prescription resolves the issue without a formal appeal.⁴

Prediabetes is another area where metformin shows up. Physicians sometimes prescribe it to patients whose blood sugar is elevated but not yet in the diabetic range, particularly when lifestyle changes alone haven’t been enough. Despite evidence supporting this use, prescribing rates for prediabetes remain low. A study of over 7,000 eligible patients in a low-income, insured population found that only about 7% were prescribed metformin for prediabetes, and among those who did get a prescription, a quarter took 280 days or longer to actually start the medication.⁵ Insurance coverage is part of the reason: if the claim is coded as prediabetes rather than diabetes, the plan may not automatically cover the drug at Tier 1, and even small cost bumps discourage initiation.

There is also a growing community of people interested in metformin as an anti-aging intervention, driven by animal research and the high-profile TAME (Targeting Aging with Metformin) clinical trial. For someone without a diabetes or prediabetes diagnosis, getting insurance to cover metformin at all is unlikely, let alone at Tier 1. Most people pursuing longevity-focused metformin use pay out of pocket, which is still inexpensive for the generic tablet but removes the tier structure from the equation entirely.

How Even Small Costs Affect Whether People Take Their Medication

You might wonder why tier placement matters so much for a drug that only costs a few dollars. The research on this is striking and consistent: even modest out-of-pocket costs measurably reduce the chance that a patient will fill and keep taking a prescribed medication.

One large study of patients with type 2 diabetes found that the relationship between cost and persistence on metformin was nonlinear. Patients in the lowest cost group had the highest rates of continuing their medication, and every step up in cost was associated with lower persistence, even when those steps were small in absolute dollar terms.⁶ Separate research found that adherence to oral antidiabetic medications dropped as copays increased from under $10 to $20 or more, with the overall proportion of days covered by medication falling noticeably across that range.⁷

The effect starts before a patient even picks up the first bottle. A study of a Northern California diabetes population found that “primary nonadherence,” meaning the patient never fills the prescription at all, increased steadily with out-of-pocket cost. When the medication was free, about 3% of patients never picked it up. At an out-of-pocket cost of $11 or more, that figure jumped to 7%.⁸ For a disease where consistent daily medication can prevent kidney damage, blindness, and amputations, those seemingly small percentages represent real people who fall off treatment because the cost created just enough friction.

This is the deeper reason metformin’s Tier 1 status matters. It is not just about saving you $5 at the pharmacy counter. Placing a first-line chronic disease drug at the lowest possible cost tier is a public health strategy designed to reduce the number of patients who skip or abandon treatment due to cost barriers. When a plan moves metformin off Tier 1 for any reason, or when a patient’s specific situation pushes them into a higher-cost scenario, the adherence data suggests that real clinical consequences follow.

Discount Programs for the Uninsured or Underinsured

If you do not have insurance, or your plan’s formulary has somehow placed your metformin formulation on a higher tier, retail pharmacy discount programs are worth knowing about. Major chains have offered generic discount programs for years, typically charging around $4 for a 30-day supply of common generics including metformin.³ Some chains offer 90-day supplies for $10 to $13. These programs do not require insurance and are available to anyone with a valid prescription.

Awareness remains a barrier. Research on low-income populations found that while roughly 72% of respondents knew about generic discount programs, utilization was far more likely when a physician or pharmacist specifically mentioned the program. Patients were about four times more likely to use a discount program when their doctor or pharmacist brought it up compared to when they had to discover it on their own.³ If cost is a concern and your provider hasn’t mentioned these programs, ask. For metformin in particular, the out-of-pocket price through a discount program is often comparable to or cheaper than a Tier 1 copay.

Prescription discount cards and apps like GoodRx and RxSaver also frequently list metformin at very low prices. These are not insurance, so they do not count toward your deductible, but for a drug this cheap, that distinction rarely matters.

The 2020 Extended-Release Recall and What It Revealed

In 2020, a string of recalls hit the generic extended-release metformin market after testing revealed the presence of NDMA, a probable carcinogen, in certain batches above acceptable limits.⁹ The recalls were not unique to metformin; NDMA contamination had already prompted massive recalls of blood pressure and heartburn medications in the years prior. But the metformin recalls were particularly disruptive because of how many patients take the drug daily.

For a time, certain ER metformin products disappeared from pharmacy shelves, and patients were switched to immediate-release versions or to ER products from manufacturers whose batches tested clean. The episode raised uncomfortable questions about the relationship between rock-bottom generic drug pricing and manufacturing quality oversight. When a 90-day supply of a drug costs $4, the profit margins for manufacturers are razor thin, and the incentive to cut corners on quality control is a legitimate concern in the generic drug supply chain.⁹

The FDA cleared the affected products after manufacturers addressed the contamination issue, and ER metformin is widely available again. But the recall is worth knowing about because it illustrates a tension baked into the generic drug model: the same market dynamics that make metformin a Tier 1 drug at negligible cost to the patient also squeeze the manufacturers who produce it. The system works well when oversight is strong, and it shows cracks when it isn’t.

When Your Tier Changes Mid-Year

Formularies are not static documents. Insurance plans can and do update their formularies throughout the year, though they are required to notify members of changes that affect their current medications. For a drug as entrenched as generic metformin, a mid-year tier change is exceptionally rare, but it can happen indirectly. A plan might restructure its entire tier system, collapsing from five tiers to three, or it might reclassify certain ER formulations differently than IR tablets.

More commonly, patients experience an effective tier change when they switch insurance plans, whether through a new employer, a marketplace enrollment, or aging into Medicare. Medicare Part D formularies vary significantly by plan, and while virtually all of them include generic metformin, the copay structure differs. Some Medicare Advantage plans have eliminated copays for Tier 1 diabetes drugs entirely as a competitive feature, while others charge a few dollars. If you are switching plans during open enrollment, checking whether your current medications remain on the same tier is one of the most practical things you can do, and for metformin specifically, confirming that your particular formulation (IR vs. ER, tablet vs. liquid) is covered at the tier you expect.

The formulary lookup tool on your plan’s website or the Medicare Plan Finder will show you the tier placement and estimated cost for any covered drug. Pharmacists can also run a test claim to see what your plan will charge before you commit to filling a prescription. For a drug that you will likely take every day for years, even a $5 per month difference adds up, and knowing your tier status before you fill is worth the two minutes it takes to check.